# US 2026/0062706 A1 · Treatment Of Pan-Cancer Phenotype With Regulator of Telomere Elongation Helicase 1 (RTEL1) Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062706 A1
- Document ID: US20260062706A1
- Status: Published application
- Kind: A1
- Application number: 19/314,288
- Filed: 2025-08-29
- Published: 2026-03-05
- Earliest claimed: 2024-08-30
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Michael Kessler; Eric Jorgenson; Adolfo Ferrando; Jing Tang; Silvia Alvarez; Kathryn Burch; Kuan-Han Wu
- Web page: https://patentgrep.com/patent/US20260062706A1

## CPC

- A61P 35/00: Antineoplastic agents
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure generally relates to the treatment of subjects having pan-cancer phenotype or at risk of developing pan-cancer phenotype by administering a Regulator of Telomere Elongation Helicase 1 (RTEL1) inhibitor to the subject.

## Claims

### Claim 1

A method of treating a subject having a pan-cancer phenotype or at risk of developing a pan-cancer phenotype, the method comprising administering a Regulator of Telomere Elongation Helicase 1 (RTEL1) inhibitor to the subject, wherein the pan-cancer phenotype comprises adrenal cancer, bladder cancer, bone cancer, cartilage cancer, brain cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, kidney cancer, oral cavity cancer, pharynx cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, stomach cancer, testicular cancer, thyroid cancer, or blood cancer.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the 1 RTEL1 inhibitor comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), and/or a short hairpin RNA (shRNA).

### Claim 6 (depends on 5)

The method of claim 5, wherein the RTEL1 inhibitor comprises an siRNA.

### Claim 7 (depends on 5)

The method of claim 5, wherein the RTEL1 inhibitor comprises an antisense nucleic acid molecule.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is also administered a pan-cancer phenotype therapeutic agent.

### Claim at position 7

9-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is RTEL1 reference or heterozygous for an RTEL1 variant nucleic acid molecule that comprises any one or more of the following genetic variations in the genomic nucleic acid molecule: 20:63687647:T:G, 20:63687688:C:G, 20:63693211:C:T, 20:63685789:A:C, 20:63662841:C:T, 20:63695551:CTG:C, 20:63667489:C:T, 20:63694876:C:T, 20:63661341:C:T, 20:63688315:G:A, 20:63662559:G:C, 20:63690137:A:C, 20:63667492:G:A, 20:63678268:T:C, 20:63690835:G:T, 20:63694489:G:A, 20:63687706:C:T, and 20:63667554:G:T, referring to the chromosome: positions set forth in the GRCh38/hg38 human genome assembly.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is RTEL1 reference or heterozygous for an RTEL1 variant nucleic acid molecule that comprises any one or more of the following genetic variations in the genomic nucleic acid molecule: 20:63667554:G:T, 20:63685789:A:C, 20:63693211:C:T (rs398123017), 20:63694489:G:A, and 20:63695551:CTG:C (rs1316931773), referring to the chromosome: positions set forth in the GRCh38/hg38 human genome assembly.

### Claim 16

A method of treating a subject having a pan-cancer phenotype or at risk of developing a pan-cancer phenotype by administering a pan-cancer phenotype therapeutic agent, the method comprising:
determining or having determined whether the subject has a Regulator of Telomere Elongation Helicase 1 (RTEL1) variant nucleic acid molecule, by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising an RTEL1 variant nucleic acid molecule; and
administering or continuing to administer the pan-cancer phenotype therapeutic agent in an amount that is the same as or less than a standard dosage amount, and/or an RTEL1 inhibitor to a subject that is RTEL1 reference;
administering or continuing to administer the pan-cancer phenotype therapeutic agent in an amount that is the same as or less than a standard dosage amount, and/or an RTEL1 inhibitor to a subject that is heterozygous for the RTEL1 variant nucleic acid molecule; or
administering or continuing to administer the pan-cancer phenotype therapeutic agent in a standard dosage amount to a subject that is homozygous for the RTEL1 variant nucleic acid molecule;
wherein the presence of the RTEL1 variant nucleic acid molecule indicates the subject has a decreased risk of developing pan-cancer phenotype; and
wherein the pan-cancer phenotype comprises adrenal cancer, bladder cancer, bone cancer, cartilage cancer, brain cancer, breast cancer, cervical cancer, colon cancer, esophagus cancer, kidney cancer, oral cavity cancer, pharynx cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, stomach cancer, testicular cancer, thyroid cancer, or blood cancer.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The method of claim 16, wherein the RTEL1 inhibitor comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), and/or a short hairpin RNA (shRNA).

### Claim 19 (depends on 18)

The method of claim 18, wherein the inhibitory nucleic acid molecule comprises an siRNA.

### Claim 20 (depends on 18)

The method of claim 18, wherein the molecule comprises an antisense nucleic acid molecule.

### Claim 21 (depends on 16)

The method of claim 16, wherein the method comprises administering or continuing to administer the pan-cancer phenotype therapeutic agent in an amount that is the same as or less than a standard dosage amount and the RTEL1 inhibitor to a subject that is heterozygous for the RTEL1 variant nucleic acid molecule.

### Claim 22 (depends on 16)

The method of claim 16, wherein the method comprises administering or continuing to administer the pan-cancer phenotype therapeutic agent in an amount that is the same as or less than a standard dosage amount and the RTEL1 inhibitor to a subject that is RTEL1 reference.

### Claim 23 (depends on 16)

The method of claim 16, wherein the RTEL1 variant nucleic acid molecule comprises a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, a missense variant, an in-frame indel variant, and/or a variant that encodes a truncated RTEL1 variant polypeptide.

### Claim 24 (depends on 16)

The method of claim 16, wherein the RTEL1 variant nucleic acid molecule comprises the genetic variation listed in Table 1, or an mRNA molecule produced therefrom, or a cDNA molecule produced from the mRNA molecule.

### Claim 25 (depends on 16)

The method of claim 16, wherein the RTEL1 variant nucleic acid molecule comprises any one or more of the following genetic variations in the genomic nucleic acid molecule: 20:63687647:T:G, 20:63687688:C:G, 20:63693211:C:T, 20:63685789:A:C, 20:63662841:C:T, 20:63695551:CTG:C, 20:63667489:C:T, 20:63694876:C:T, 20:63661341:C:T, 20:63688315:G:A, 20:63662559:G:C, 20:63690137:A:C, 20:63667492:G:A, 20:63678268:T:C, 20:63690835:G:T, 20:63694489:G:A, 20:63687706:C:T, and 20:63667554:G:T, referring to the chromosome: positions set forth in the GRCh38/hg38 human genome assembly.

### Claim 26 (depends on 16)

The method of claim 16, wherein the RTEL1 variant nucleic acid molecule comprises any one or more of the following genetic variations in the genomic nucleic acid molecule: 20:63667554:G:T, 20:63685789:A:C, 20:63693211:C:T (rs398123017), 20:63694489:G:A, and 20:63695551:CTG:C (rs1316931773), referring to the chromosome: positions set forth in the GRCh38/hg38 human genome assembly.

### Claim at position 21

27-28. (canceled)

### Claim 29

A method of identifying a subject having an increased risk of developing a pan-cancer phenotype, the method comprising:
determining or having determined the presence or absence of a Regulator of Telomere Elongation Helicase 1 (RTEL1) variant nucleic acid molecule in a biological sample obtained from the subject;
wherein:
when the subject is RTEL1 reference, then the subject has an increased risk of developing the pan-cancer phenotype; and
when the subject is heterozygous or homozygous for the RTEL1 variant nucleic acid molecule, then the subject has a decreased risk of developing the pan-cancer phenotype.

### Claim at position 23

30-57. (canceled)
